Melanoma Combination Drug Therapy Increases Survival Rate

Posted on September 22, 2015 in News

Written by Dr. McCammon

Learn more about the author

New Combination Drug Therapy May Increase Survival Rates for Melanoma

pill bottle open with pills inside

According to recent clinical trials performed by Novartis, the Swiss pharmaceutical giant, a new combination drug therapy, combining drugs Tafinlar (dabrafenib) and Mekinist (trametinib) increases survival rate in melanoma patients versus monotherapy with vemurafenib alone.

“Swiss drug major Novartis (VX: NOVN) said a Phase III combination study for skin cancer has shown a significant overall survival benefit for patients.

The patients were treated with a combination of Tafinlar (dabrafenib) and Mekinist (trametinib) against vemurafenib monotherapy.

Caroline Robert,  head of Dermatology, Institute Gustave-Roussy, said: “It is remarkable to see so many patients with BRAF V600E/K mutation-positive metastatic melanoma having long term responses and obtaining a significant decrease of the risk of death as compared with vemurafenib monotherapy. This is the second Phase III trial of Tafinlar + Mekinist combination therapy to demonstrate a significant overall survival benefit over BRAF inhibitor monotherapy, further establishing Tafinlar + Mekinist as a standard of care for patients fighting BRAF V600 mutation-positive metastatic melanoma.”

Read the full article.